591P Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based genomic profile and molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study
Shin Kobayashi(National Cancer Center Hospital East), Yoshiaki Nakamura(National Cancer Center Hospital East), Yoshinori Kagawa(Osaka International Cancer Institute), Soichiro Natsume(Tokyo Metropolitan Komagome Hospital), Akiko Takahashi(Japanese Foundation For Cancer Research), Yasuhiro Shimizu(Aichi Cancer Center), Daisuke Nobuoka(Fukuyama City Hospital), Manabu Shiozawa(Kanagawa Prefectural Hospital Organization), Akio Shiomi(Shizuoka Cancer Center), Eiji Oki(Kyushu University), Akinobu Taketomi(Hokkaido University), Takefumi Niguma(Okayama Saiseikai General Hospital), Takeshi Takamoto(National Cancer Center Hospital East), Takeshi Kato(Osaka National Hospital), Yoshiaki Takahashi(The Cancer Institute Hospital), Junichiro Yamauchi(Sendai Kousei Hospital)
Cited by 5
Related Papers
Exosomes maintain cellular homeostasis by excreting harmful DNA from cells
|Nature Communications|2017|748
Randomized clinical trial of adjuvant gemcitabine chemotherapy <i>versus</i> observation in resected bile duct cancer
|British journal of surgery|2018|401
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Phase I Trial of a Glypican-3–Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
|Clinical Cancer Research|2012|304
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
|Nature Reviews Clinical Oncology|2021|301